Wexford Capital’s Edwards Lifesciences EW Stock Holding History

Wexford Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,291	Closed	-$103K	–	328
2020 Q3	$103K	Buy	+1,291	New	+$101K	0.03%	131

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wexford Capital's EW Position: Q4 2020 in Review

Wexford Capital sold out of Edwards Lifesciences (EW) in Q4 2020, closing a stake of 1,291 shares — an estimated $103K sold.

Wexford Capital first reported a position in EW in Q3 2020 and held it in 1 quarter. The position peaked at $103K in Q3 2020. 1,158 funds tracked by Wall St. Rank hold EW as of Q4 2020.

Wexford Capital reported no remaining Edwards Lifesciences position as of Q4 2020 after selling out during the quarter.
Wexford Capital sold 1,291 Edwards Lifesciences shares in Q4 2020, an estimated $103K.
Wexford Capital first reported a position in Edwards Lifesciences in Q3 2020 and held it in 1 quarter.
Wexford Capital's Edwards Lifesciences position peaked at $103K in Q3 2020.
1,158 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2020.

Based on Wexford Capital's 13F filing for Q4 2020, filed 16 Feb 2021.